Bill Text: IL HB3097 | 2019-2020 | 101st General Assembly | Chaptered
Bill Title: Amends the Illinois Public Aid Code. Requires the Department of Human Services to develop in collaboration with an academic institution a program designed to provide prescribing physicians under the medical assistance program with an evidence-based, non-commercial source of the latest objective information about pharmaceuticals. Provides that the prescriber education program shall consist of a web-based curriculum and an academic educator outreach and shall contract with clinical pharmacists to provide scheduled visits with prescribing physicians to update them on the latest research concerning medication usage and new updates on disease states in an unbiased manner. Provides that education provided under the prescriber education program shall include disease-based educational modules on the treatment of chronic non-cancer pain, diabetes, hypertension, and other specified diseases and that such modules shall be reviewed and updated on an annual or as-needed basis. Provides that additional resources provided under the prescribing education program shall include, but not be limited to: (i) a drug information response center available to prescribing physicians that provides thorough and timely in-depth answers to any questions a prescribing physician may have within 48 hours after a question is received; and (ii) information on drug utilization trends within individual and group practices.
Sponsorship: Moderate Partisan Bill (Democrat 15-2)
Status: (Passed) 2019-08-09 - Public Act . . . . . . . . . 101-0278 [HB3097 Detail]
Download: Illinois-2019-HB3097-Chaptered.html
| ||||
| Public Act 101-0278 | ||||
| ||||
| ||||
AN ACT concerning public aid.
| ||||
Be it enacted by the People of the State of Illinois,
| ||||
represented in the General Assembly:
| ||||
Section 5. The Illinois Public Aid Code is amended by | ||||
adding Section 12-4.52 as follows:
| ||||
(305 ILCS 5/12-4.52 new) | ||||
Sec. 12-4.52. Prescriber education. | ||||
(a) The Department of Healthcare and Family Services shall | ||||
develop, in collaboration with a public university that has a | ||||
Doctor of Pharmacy Professional Program and is located in a | ||||
county with a population of more than 3,000,000, a program | ||||
designed to provide
prescribing physicians under the medical | ||||
assistance program with an evidence-based, non-commercial | ||||
source of the latest
objective information about | ||||
pharmaceuticals. Information shall be
presented to prescribing | ||||
physicians by specially trained pharmacists, nurses, or
other | ||||
health professionals to assist prescribing physicians in | ||||
making
appropriate therapeutic recommendations. | ||||
(b) The prescriber education program shall consist of 2 | ||||
components: a web-based curriculum and an academic educator | ||||
outreach. The program shall contract with clinical pharmacists | ||||
to provide scheduled visits with prescribing physicians to | ||||
update them on the latest research concerning medication usage | ||||
and new updates on disease states in an unbiased manner. | ||
(c) Education provided under the prescriber education | ||
program shall include, but not be limited to, disease-based | ||
educational modules on the treatment of chronic non-cancer | ||
pain, diabetes, hypertension, hyperlipidemia, respiratory | ||
syncytial virus, and nicotine dependence. New modules may be | ||
created periodically as needed and existing module content | ||
shall be reviewed and updated on an annual or as-needed basis. | ||
Educational modules provided under the program shall provide | ||
prescribing physicians with continuing medical education | ||
credit. | ||
(d) Additional resources provided under the prescriber | ||
education program shall include, but not be limited to, the | ||
following: | ||
(1) a drug information response center available to | ||
prescribing physicians that provides thorough and timely | ||
in-depth answers to any questions a prescribing physician | ||
may have within 48 hours after a question is received; and | ||
(2) information on drug utilization trends within | ||
individual and group practices.
| ||
